Potential therapeutic application of EP3 agonists
| Agonist | Route | Dose | Species | Experimental Model | Indication | Reference |
|---|---|---|---|---|---|---|
| MB 28767 | Intravenous | 2 pmol · kg−1 · min−1 | Pig | Occlusion/reperfusion | Cardiac infarction | Hohlfeld et al., 2000 |
| MB 28767 | Intracisternal | 1 fg–30 ng per animal | Mouse | Naloxone-induced withdrawal jumping | Opiate withdrawal syndrome | Nakagawa et al., 1995 |
| ONO-AE-248 | Subcutaneous | 10 μg/kg | Mouse | Ovalbumin induced asthma | Asthma | Kunikata et al., 2005 |
| TEI-3356 | Intravenous | 1 μg · kg−1 · h−1 | Rat | Occlusion/reperfusion | Cardiac infarction | Zacharowski et al., 1999 |
TEI-3356, 5-(-7-hydroxy-6-(4-hydroxy-4-methyl-1-octenyl)bicyclo(3.3.0)oct-2-en-3-yl)pentanoic acid.